Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
JIB

Big Data Research Platform Aggregates, Interprets Molecular, Life Sciences Data

By BiotechDaily International staff writers
Posted on 29 Jul 2013
A new research platform’s Big Data technology enables users to apply genomic data from disparate sources in innovative and helpful ways across life sciences research.

Boehringer Ingelheim (Ingelheim, Germany) has signed a multiyear renewal agreement to the NextBio research platform (Santa Clara, CA, USA). The new agreement also extends the user base for NextBio across Boehringer Ingelheim’s global research organization.

“Boehringer Ingelheim is one of the world’s 20 leading pharmaceutical companies and has been a user of NextBio Research for the past year,” said Saeid Akhtari, NextBio president and chief executive officer. “This expanded license and broadened access to the NextBio Research platform is a strong endorsement of our technology’s value for enabling life scientists to quickly examine and understand their data in the context of published research worldwide.

“NextBio Research provides a comprehensive platform for exploratory, preclinical and early translational research in drug discovery and biotechnology research,” Mr. Akhtari added. “Integrating proprietary analysis results with extensive curated content, NextBio enhances researchers’ ability to design experiments, test hypotheses, and validate results, leading to better target analysis, understanding of disease mechanisms, and analysis of results across species.”

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. It operates globally with 140 affiliates and more than 46,000 employees. The company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine. In 2012, Boehringer Ingelheim achieved net sales of about EUR 14.7 billion. R&D expenditure in the business area Prescription Medicines corresponds to 22.5% of its net sales.

NextBio provides a cutting-edge scientific platform to aggregate and interpret large quantities of molecular and other life sciences data for research and clinical applications. NextBio’s platform integrates data from multiple repositories and diverse technologies by way of a unique correlation engine, which precomputes billions of significant connections between disparate public and proprietary clinical and research data. This feature enables interpretation of an individual’s molecular data.

Furthermore, the platform provides translational researchers with the capability to gaze across the clinical and molecular data of entire populations for clinical trial stratification and selection, hypotheses generation, and biomarker discovery. NextBio Clinical, which recently passed an independent HIPAA audit, is designed for seamless integration with existing clinical and research systems. Backed by highly scalable, Big Data technology, it is capable of analyzing petabytes of data. NextBio’s platform is delivered as a software as a service (SaaS) system, resulting in fast deployment and rapid return on investment.

NextBio is currently used by researchers and clinicians in over 50 top commercial and academic institutions.

Related Links:

Boehringer Ingelheim
NextBio



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Diagram illustrates the innovative process that could lead to more effective drugs against influenza infection (Photo courtesy of the Hebrew University of Jerusalem).

Researchers Show How the Influenza Virus Blocks Natural Killer Cell Recognition

A team of molecular virologists has described how the influenza virus evolved a defense mechanism to protect it from attack by the immune system's natural killer (NK) cells. The recognition of pathogen-infected... Read more

Drug Discovery

view channel
Image: Synthetic ion transporters can induce apoptosis by facilitating chloride anion transport into cells (Photo courtesy of the University of Texas, Austin).

Experimental Drug Kills Cancer Cells by Interfering with Their Ion Transport Mechanism

An experimental anticancer drug induces cells to enter a molecular pathway leading to apoptosis by skewing their ion transport systems to greatly favor the influx of chloride anions. To promote development... Read more

Therapeutics

view channel
Image: Liver cells regenerated in mice treated with a new drug (right) compared with a control group (center) after partial liver removal. Healthy liver cells are shown at left (Photo courtesy of Marshall et al, 2014, the Journal of Experimental Medicine).

New Drug Triggers Liver Regeneration After Surgery

Investigators have revealed that an innovative complement inhibitor decreases complement-mediated liver cell death, and actually stimulates postsurgery liver regrowth in mice. Liver cancer often results... Read more

Lab Technologies

view channel

Genome-Wide Mutation-Searching Computational Software Designed for Genomic Medicine

Analysis software cross-references a patient’s symptoms with his genome sequence to help physicians in the diagnosis of disease. This software was created by a team of scientists from A*STAR’s Genome Institute of Singapore (GIS), led by Dr. Pauline Ng. The research findings were published August 3, 2014, in the journal... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.